Eli Lilly to Offer Higher Doses of Obesity Drug Zepbound at Discounted Prices
Eli Lilly is expanding its offerings of its hit weight-loss drug Zepbound for people who want to pay cash instead of using their health plans, and reducing prices for certain dosages.
Eli Lilly to lower price of Zepbound vials, offer more doses
Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepbound in vials and lower the prices of the doses it already sells.
Eli Lilly cuts prices for Zepbound weight-loss drug again
Pharmaceutical giant Eli Lilly is once again expanding the supply of its weight-loss drug Zepbound and cutting the cost for patients that don't have insurance.
Novo Nordisk cuts Wegovy prices, following similar move by Zepbound-maker Eli Lilly
Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for people without insurance. Danish drugmaker Novo Nordisk said Wednesday that it will drop prices 23% for all doses of Wegovy. The new monthly price of $499, down from $650, takes effect immediately.
Wegovy price cut: Novo Nordisk cuts the price of the weight-loss drug for the uninsured
After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight-loss drug Wegovy.
Wegovy Gets Cheaper! Novo Nordisk Takes on Eli Lilly as Obesity Drug Battle Heats Up
Novo Nordisk A/S (NVO) has slashed prices for its blockbuster weight-loss drug Wegovy as competition in the obesity drug market heats up, with
Popular weight-loss drugs get cheaper: Novo Nordisk and Eli Lilly cut prices
Danish drugmaker Novo Nordisk said Wednesday that it will drop prices 23% for all doses of Wegovy. The new monthly price of $499 takes effect immediately.
InnovationRx: Eli Lilly Has Stockpiled Nearly $550 Million Of Its Next Obesity Drug
In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...
Fierce Pharma3d
In FDA obesity drug battle with compounders, Texas court allows Novo Nordisk to weigh in
As a federal court in Texas hears a case pitting the FDA versus compounders who want to continue to manufacture cheaper ...
BioSpace5d
FDA, Other Experts Seek to Redefine Obesity and Prioritize Maintenance Treatment
Two recent documents—one from the FDA, the other from a commission organized by The Lancet Diabetes & Endocrinology—indicate ...
Health News Florida4d
Consumers can buy Zepbound and Wegovy direct from drugmakers if they pay cash
Eli Lilly is offering vials of its weight-loss drug Zepbound to patients at a discount — but only if they skip their ...
Yahoo Finance2d
Eli Lilly and Company (LLY)
Eli Lilly and Company (NYSE: LLY ... for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity.1 Zepbound may help adults with moderate-to-severe obstructive sleep apnea ...
BioSpace4d
Tariff Threat Continues, More Meetings Cancelled, AbbVie Makes Obesity Play, More
Pfizer reacts to Donald Trump’s tariff threats on big pharma, another regulatory meeting is canceled under RFK Jr., AbbVie ...
Zepbound maker Eli Lilly announces $27 billion investment in US drug manufacturing as Trump threatens tariffs
Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional ...
Eli Lilly and Company (LLY): Among the Best Stocks to Buy According to Lone Pine Capital
We recently compiled a list of the Top 10 Stocks to Buy According to Lone Pine Capital. In this article, we are going to take ...